RBC raises target for Rhythm Pharmaceuticals stock to USD 159

Published on 10/08/2026 at 20:32 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

RBC kept Outperform with a USD 159.00 target on October 8, 2026. Rhythm Pharmaceuticals stock costs EUR 80.50 on October 8, 2026 after EUR 78.75.

Key points in brief

RBC Capital kept an Outperform rating and raised its Rhythm Pharmaceuticals target from USD 155.00 to USD 159.00 on October 8, 2026.
Second-quarter 2026 revenue reached USD 71.25 million, up 19.00 percent sequentially from USD 60.10 million.
Rhythm Pharmaceuticals stock was at EUR 80.50 at Lang & Schwarz on October 8, 2026 at 8:29 p.m. CEST, plus 2.22 percent versus EUR 78.75.
The next scheduled quarterly report is November 3, 2026, before the market opens.

RYTM, US76243J1051, Illustration mit AI erstellt.

Rhythm Pharmaceuticals (ISIN US76243J1051) was trading at EUR 80.50 at Lang & Schwarz on October 8, 2026 at 8:29 p.m. CEST, up 2.22 percent versus the prior close of EUR 78.75. On the same date, GuruFocus reported that RBC Capital kept an Outperform rating and raised its target from USD 155.00 to USD 159.00. The target increase was 2.58 percent.

Three dated catalysts and figures

On August 4, 2026, Rhythm Pharmaceuticals reported second-quarter global net product revenue of USD 71.25 million for IMCIVREE, up 19.00 percent sequentially from USD 60.10 million in the first quarter, according to Backpack. The company also reported diluted earnings per share of minus USD 0.73 for the quarter.

On September 10, 2026, MarketScreener reported data from 30 pediatric patients with acquired hypothalamic obesity treated with setmelanotide for as long as 18 months. The report said the analysis showed reductions in body mass index and hunger scores.

On September 22, 2026, Makkler carried Rhythm Pharmaceuticals' announcement that Health Canada approved IMCIVREE for weight management in adults and children aged 4 years and older with acquired hypothalamic obesity.

What does the target change mean?

RBC's USD 159.00 target stands USD 4.00 above its previous USD 155.00 target, a 2.58 percent increase. The revised target remains separate from the Lang & Schwarz euro quotation, so the two currencies cannot be used to calculate a single upside figure.

The operating comparison is more direct. Second-quarter revenue of USD 71.25 million exceeded first-quarter revenue of USD 60.10 million by USD 11.15 million, while the company remained loss-making with a second-quarter net loss of USD 49.30 million.

Next report is dated November 3

MarketBeat lists November 3, 2026 as Rhythm Pharmaceuticals' next reporting date, before the market opens, for third-quarter 2026 results. The listed consensus revenue estimate is USD 84.84 million, above the USD 71.25 million reported for the second quarter.

Rhythm Pharmaceuticals has a USD 6.2 billion market capitalization as of October 8, 2026. Its Nasdaq quotation was USD 90.25 at 2:30 p.m. ET on October 8, 2026, while the 52-week range was USD 74.50 to USD 122.20.

Stock trades after the Xetra close

At Lang & Schwarz, Rhythm Pharmaceuticals stock was trading at EUR 80.50 on October 8, 2026 at 8:29 p.m. CEST, plus 2.22 percent versus the prior close of EUR 78.75. The further course of trading is shown by the continuously updated real-time quote of Rhythm Pharmaceuticals stock.